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MONICA N. STARKMAN, MD, MS, OLIVER G. CAMERON, MD, PHD,
RANDOLPH M. NESSE, MD, AND THOMAS ZELNIK, MD
We studied the correlation of plasma and urinary epinephrine (E) and norepinephrine (NE)
levels with anxiety symptoms in three patient groups: 1) pheochromocytoma (PH+) (n = 17);
2) hypertensives with elevated catecholamine levels shown not to have a PH (PH—) (n = 25);
and 3) patients with panic disorder (PD) (n = 23). Structured interviews and four self-rated
anxiety scales were used, the SCL-90R Anxiety and Phobic Anxiety scales, and the Spielberger
State/Trait Anxiety Inventories. The SCL-90R Somatization scale (which measures 12 somatic
symptoms) was also utilized. None of the PH+ patients met DSM-III criteria for PD. Two met
criteria for generalized anxiety disorder (GAD). Of the PH— patients, two had PD, two had
GAD. and three had both. Urinary and plasma E did not show significant positive correlations
with any of the four anxiety scales in any of the three patient groups. In both the PH+ and
PH— groups, E was significantly correlated with the SCL-90R Somatization scale. NE was not
significantly correlated with any of the four anxiety scales in the PH+ group. In contrast, in
the PH— group, plasma NE was significantly correlated with anxiety on all anxiety scales (r =
+0.55 to +0.77, p < 0.05). Furthermore, in the PH- group, plasma NE was significantly
correlated with those items of the SCL-90R Anxiety scale measuring the cognitive rather than
the noncognitive symptoms of anxiety. In the PD group as well, plasma NE showed a significant
correlation with the SCL-90R Anxiety Scale (r = +0.67, p < 0.05). Taken together, our
observations suggest that: 1) the effects of catecholamines in the periphery derived from a
source independent of nervous system control (such as a PH) are not sufficient to elicit an
anxiety disorder meeting DSM-III criteria; and 2) in patients without an autonomous source of
peripheral catecholamines, NE in the periphery results from sympathetic nervous system
activation and probably reflects, rather than causes, anxiety.
INTRODUCTION
Recent refinements in the classification
of anxiety disorders and the availability
of more efficacious pharmacologic treat-
ments have renewed interest in the
pathophysiology of anxiety. In this regard,
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one area of both historical and current
interest is the role played by peripheral
as well as central catecholamines.
Three lines of investigation bear on this
question. The first addresses catechol-
amine elevation in response to psychoso-
cial stimuli. Various psychosocial stimuli
are known to influence catecholamine
levels, but the exact relationship between
the kinds of stimuli and the patterns of
response remains uncertain. Threat has
long been known to induce catechol-
amine secretion in a variety of species (1).
Subsequent research has shown that a
wide variety of noxious physical or psy-
chological stimuli release catecholamines
(2, 3). Pleasant arousal is also associated
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with elevated catecholamine levels (2).
More recently, anxiety induced by in vivo
flooding in phobic patients was found to
stimulate catecholamine excretion inde-
pendent of pain or muscular activity (4).
Some studies of catecholamine secretion
suggested that epinephrine (E) release was
associated with fear and anxiety and nor-
epinephrine (NE) with aggression (5). Ma-
son (6) proposed that E was increased in
situations characterized by novelty and
uncertainty, whereas NE rose in unpleas-
ant but familiar conditions. Levi (7] re-
ported that either positive or negative
emotional arousal produces rises in both
mean E and NE levels. In phobic patients
undergoing flooding therapy, NE showed
a more consistent elevation, whereas E,
when elevated, showed a greater magni-
tude of increase (4). Although patients
with panic disorder were thought to show
MHPG elevation during situational panic
attacks (8), it now appears that panic itself
has little effect on plasma MHPG levels
(9), and that venous plasma E is un-
changed, whereas plasma NE is either
unchanged or minimally elevated during
spontaneous panic attacks [10). In sum-
mary, catecholamines have been shown
to change in response to psychological
stimuli, but no simple principle explains
all of the relationships observed.
The second line of investigation ad-
dresses symptoms that result from the
administration of catecholamines or "cat-
echol-like" compounds. Isoproterenol in-
duces physical symptoms in normal sub-
jects, including palpitations, dyspnea, and
sweating (11). In normal subjects, the
emotional reaction to intramuscular in-
jection of E is largely determined by the
associated social setting and expectations
(12); in a neutral setting, both E and NE
have similar effects, neither inducing spe-
cific or strong emotions, although their
physical effects simulate a state of arousal
(2). In patients with panic disorder, iso-
proterenol may precipitate anxiety at-
tacks (13), even though these patients
have /3-adrenergic receptors that are less
sensitive than those of normal subjects
(14). Thus, catecholamines change psy-
chological states and psychological events
change catecholamine levels; the inter-
actions are complex.
The third line of investigation deals
with resting levels of catecholamines in
psychiatric patients and normal subjects.
In some studies, while patients with panic
disorder had elevated resting plasma lev-
els of E, NE, and MHPG (14, 15), anxiety
ratings were not correlated with the cate-
cholamine levels (15). Compared to nor-
mal subjects, some panic disorder patients
show elevated levels of nighttime urinary
NE and, to a lesser extent, E (16), and tend
to have elevated urinary excretion of
MHPG (17). As for patients with general-
ized anxiety disorder, they may or may
not have elevated plasma catecholamine
levels (18). In patients with depressive
disorder, plasma catecholamine levels
correlate better with anxiety ratings than
with depression ratings (19), and anxious
depressives in particular also have ele-
vated cerebrospinal fluid (CSF) NE levels
(20). In normal subjects, one study re-
ported high trait anxiety as measured by
the Spielberger Trait Anxiety Scale to be
positively correlated with higher plasma
MHPG elevations (21), but in another
study, plasma MHPG correlated nega-
tively with trait anxiety (22). However,
CSF MHPG correlated positively with
state anxiety just prior to lumbar punc-
ture (22). All in all, while resting cate-
cholamines appear to be somewhat ele-
vated in patients with panic disorder and
130 Psychosomatic Medicine 52:129-142 (1990)PERIPHERAL CATECHOLAMINE LEVELS AND ANXIETY
are possibly elevated in patients with
more generalized anxiety, stronger gen-
eralizations are not yet warranted.
Thus, despite previous and current re-
search, the question of whether periph-
eral E and NE play an etiologic role in
producing anxiety, as suggested by the
James-Lang hypothesis, or are simply con-
comitants of the state of arousal, has still
not been satisfactorily answered.
In order to explore further the relation-
ship between peripheral catecholamine
levels and anxiety, we studied the corre-
lation of E and NE with anxiety ratings in
three patient groups with special features
that bear on this question. One group of
patients had pheochromocytomas, tumors
of adrenal medullary cells that release
high levels of catecholamines into the cir-
culation. They do so autonomously and
not through autonomic nervous system
stimulation, responding instead to such
stimuli as change in position. Since pe-
ripheral catecholamines do not appear to
cross the blood-brain barrier in physiolog-
ically significant amounts (23-25], these
patients provide an opportunity to study
the effect of autonomously secreted ele-
vated peripheral catecholamine levels on
symptoms of anxiety. The second group
of subjects were patients with hyperten-
sion and/or elevated catecholamine
levels, who were initially suspected of
having a pheochromocytoma but were
subsequently shown not to have such a
tumor. The elevated peripheral catechol-
amines in these patients result not from
an autonomous tumor but from sympa-
thetic nervous system activity and sym-
pathetic stimulation of the adrenal me-
dulla, presumably under the complex
control of the central nervous system.
This group was of interest because the
high mean catecholamine levels and wide
variation of values among individuals in
the group can provide information regard-
ing the association of anxiety symptoms
and elevated catecholamine levels which
result from sympathetic nervous system
activity.
We studied one additional group of pa-
tients for comparison. This third group
consisted of patients meeting DSM-III cri-
teria for panic disorder or for agoraphobia
with panic attacks. This group permitted
assessment of whether NE and/or E levels
are correlated with the somatic and/or
cognitive symptoms of anxiety in patients
with anxiety disorders who characteris-
tically have mildly rather than markedly
elevated catecholamine levels.
We report here that there were no sig-
nificant correlations of anxiety symptoms
with peripheral NE or E levels in the
patients with pheochromocytoma. In con-
trast, in the patients without a pheochro-
mocytoma and in the panic disorder pa-
tients, anxiety correlated significantly
with plasma NE but not with plasma E.
METHODS
Subjects with Actual or Suspected
Pheochromocytoma
Subjects were recruited through the University
of Michigan Medical Center Nuclear Medicine Unit,
an international referral center which provided a
unique opportunity to study patients with suspected
pheochromocytoma. The presence of pheochromo-
cytoma was determined by scintigraphic imaging
after the injection of [
13lI]mefa-iodobenzyl guanidine
([
131I]MIBG). This compound resembles NE in molec-
ular structure and is thought to enter the adrenergic
tissue of pheochromocytomas by the same uptake
mechanism (26).
During a 9-month period, all patients referred for
an MIBG scan because of suspected pheochromocy-
toma were evaluated. Seventeen patients were sub-
sequently determined to have a pheochromocytoma.
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This diagnosis was established by: a) plasma and
urine catecholamine and urine catecholamine me-
tabolite levels; b) abnormal scintigraphic images
with [
131I]MIBC, which is highly specific for pheo-
chromocytoma; and c) the histologic appearance of
tumor tissue, when available. Fourteen patients
were Caucasian, 2 were Afro-American, and 1 was
American Indian. Thirteen were male and 4 were
female. Their mean age was 42.5, with a range of 18
to 68 years. Fourteen of these pheochromocytoma-
positive patients had sustained persistent hyperten-
sion, 2 had paroxysmal hypertension, and 1 was
normotensive. Eleven of these patients were receiv-
ing a-adrenergic blocking agents, and 8 were receiv-
ing /J-adrenergic blocking agents. While we would
have preferred to study patients drug-free, most had
significant hypertension, and antihypertensive med-
ication could not be withdrawn solely for purposes
of this study. Elevated blood pressure and heart rate
in most of these patients, however, indicated contin-
uing effects of the excessive catecholamine levels
despite pharmacotherapy. One patient was receiving
a benzodiazepine. No patient was receiving antide-
pressant or antipsychotic medication.
Twenty-five patients who had an MIBG scan were
found not to have a pheochromocytoma. Twenty-
three of these patients were Caucasian, 2 were Afro-
American. Fifteen were male and 10 were female.
Their mean age was 40, with a range of 21 to 61
years. Twenty of these 25 pheochromocytoma-neg-
ative patients had hypertension, 12 persistent and 8
paroxysmal. At evaluation. 6 patients were receiving
a-adrenergic blocking agents, and 8 were on /3-ad-
renergic blocking agents. Two of 25 patients were
receiving benzodiazepine medication. None was re-
ceiving antidepressant medication, and 1 was receiv-
ing antipsychotic medication.
Subjects with Panic Disorder
Twenty-three patients with panic disorder or ago-
raphobia with panic attacks were studied. These
patients had requested treatment at the University
of Michigan Anxiety Disorders Program, and were
the same individuals reported on in prior publica-
tions (14, 27). Diagnoses were established according
to DSM-III criteria (28) after a clinical examination
by a psychiatrist experienced in diagnosing anxiety
disorders (O.G.C., R.M.N.). All subjects were Cau-
casian. Five were male, and 18 were female. Their
mean age was 32, with a range of 18 to 53. All
subjects were physically healthy (except for mitral
valve prolapse in 7), were normotensive, and not
taking any medication. All but 2 subjects had been
medication-free for a month or more. One patient
had taken diazepam and trifluoperazine. and an-
other had taken diazepam and naldolol until two
weeks before the study. Fourteen of these 23 patients
provided both plasma and urine specimens for cate-
cholamine level studies, while the remaining 9 pro-
vided urine specimens only.
Normal Subjects
In order to obtain a comparison group for levels
of catecholamine elevation, plasma and urinary E
and NE were studied in a group of nine normal
healthy subjects. Seven were male and two female,
with a mean age of 26 and a range of 20-34 years.
Informed consent was obtained from each patient
and normal subject after the nature of the study was
fully explained.
Psychiatric Evaluation and Self-rated
Scales
A full description of the psychiatric evaluation
and self-rated scales used has been reported previ-
ously (29). Patients being tested for a suspected phe-
ochromocytoma were given a psychiatric evaluation
during the 3-day period of their MIBG scan protocol.
The interview was designed to collect data that
would bear on the diagnoses of panic disorder, gen-
eralized anxiety disorder, and major depressive ep-
isodes, as defined by the Diagnostic and Statistical
ManuaJ of Mental Disorders (Third Edition) (DSM-
III) (28).
The psychological and physical symptoms char-
acterizing paroxysmal episodes ("attacks"), as well
as chronic symptoms, were assessed for each indi-
vidual in the suspected pheochromocytoma group.
A description of the first episode (prior to the initi-
ation of antihypertensive medication) was obtained,
as well as information about any changes in symp-
tom profile over time or after the initiation of med-
ication.
For all three patient groups, each subject com-
pleted the Symptom Checklist-90-Revised (SCL-
90R), a self-report symptom inventory designed to
measure current psychological symptom status
rather than personality (30). The SCL-90R includes
an Anxiety scale that reflects levels of somatic and
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psychic anxiety, a Phobic Anxiety scale that con-
tains items related to agoraphobia, and a Somatiza-
tion scale that reflects distress arising from percep-
tions of bodily functions. The Spielberger State/Trait
Anxiety Inventory (31) was also administered to
each subject being tested for pheochromocytoma.
Psychological test scores and DSM-III diagnoses
were established before knowledge of patients'
MIBG scan results or catecholamme levels.
Hormone Measurements
Patients with suspected pheochromocytoma were
tested for plasma E and NE on the first morning of
their evaluation prior to MIBG study. An indwelling
catheter was placed in an arm vein, and patients
rested supine for 30 min before a single blood spec-
imen was drawn. Patients also collected a 12-hr
overnight urine specimen at home, refrigerated the
sample, and brought it with them on the morning
that blood was to be drawn. For purposes of this
analysis, values of the 12-hr overnight urine collec-
tion were multiplied by 2 to give an estimate of a
24-hr value. It should be noted that these estimates
do not reflect circadian variability (slightly greater
excretion during the daytime).
Plasma levels of E and NE were determined by a
radioenzymatic method (32). Urinary concentrations
of unconjugated NE and E were determined by the
method of von Euler and Lishajko (33). For panic
disorder patients and normal subjects, blood speci-
mens were also drawn via an indwelling catheter
after patients rested supine for 20, 30, and 40 min; a
mean value for these three time points was calcu-
lated. Urines were collected as two 12-hr specimens,
and a mean value for the two specimens was used
in the data analysis. Specimens were processed as
described previously (14, 27).
Statistical Methods
Histograms revealed that the raw values of hor-
mone levels in plasma and urine were not normally
distributed, especially for pheochromocytoma-posi-
tive patients. Natural log transformations produced
mnrp nnrmal HisMhiiHnnQ anH wprp thprpfnrp ncprl
mone levels in each of the three patient groups.
Because of the number of correlations studied, we
elected to accept only correlation coefficients both
statistically significant and of a magnitude of + 0.40
or greater. Given the sample size and our interest in
patterns of relationships within a group and across
groups, rather than the statistical significance of any
single correlation per se, we did not adjust the sig-
nificance level, and accepted a 0.05 level of signifi-
cance despite the fact that this may yield an over-
estimate of the number of statistically significant
correlations.
RESULTS
Mean Catecholamine Levels of
Pheochromocytoma-positive,
Pheochromocytoma-negative, and
Panic Disorder Patients
The mean catecholamine levels (±SD)
in plasma and urine for all groups are
shown in Table 1. Mean levels in nine
normal subjects are also given for com-
parison. As can be seen by inspection,
compared to normal levels, the mean
catecholamine levels were massively el-
evated in the pheochromocytoma-posi-
tive group, substantially elevated in the
pheochromocytoma-negative group, and
somewhat elevated in the panic disorder
group.
DSM-III Diagnoses and Their
Association with Catecholamine
Levels
Pheochromocytoma-positive patients.
For the 3-week period preceding the eval-
uation, 12 of the 17 pheochromocytoma-
positive patients experienced at least one
paroxysmal symptom episode. Headache
was the most prominent physical symp-
tom during these episodes; sweating, rest-
lessness, nausea, palpitations and tachy-
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TABLE 1. Epinephrine and Norepinephrine Levels in Pheochromocytoma-positive,
Pheochromocytoma-negative, Panic Disorder Patients and Normal Subjects
Pheochromocytoma-positive (N = 17)
Pheochromocytoma-negative (N = 25)
Panic disorder (N = 23)
Normal subjects (N = 9)
Plasma E
(pg/ml)
950 ± 2623-
105 ±288
52 ±25
31 ±24
Urine E
(Mg/24 hr)
105 ± 191
10 ±9
13 ± 4
8±3
Plasma NE
(pg/ml)
2376±1778
363 ± 259
298 ± 85
222 ± 38
Urine NE
(Mg/24 hr)
432 ± 307
47 ±29
33 ±8
18±5
1 Values are means ± SD.
cardia, shortness of breath, and epigastric
distress also were frequent. Because of the
type and number of somatic symptoms
they described, 9 of the 17 patients met
DSM-III criteria for the physical concom-
itants of panic attack. However, none of
the 17 patients met DSM-III criteria for
panic disorder. Although some experi-
enced psychological symptoms such as
alertness, wariness, and uneasiness, es-
pecially during paroxysmal episodes, they
denied experiencing the severe apprehen-
sion or fear bordering on terror character-
istic of patients with panic disorder. They
did not seek out others, as patients with
anxiety attacks do, but preferred to rest
in a quiet room alone until the paroxys-
mal attack ceased. Although concerned
about the potential dangers of hyperten-
sion, most patients did not experience the
intense fear of sudden death reported by
patients with panic disorder. After the
first attack and reassurance that their
symptoms were not due to a heart attack,
they simply waited for subsequent attacks
to end. No patient manifested anticipatory
anxiety or avoided going to work because
of symptoms. No patient developed ago-
raphobia. (A comprehensive description
of physical and mental symptoms in this
group of patients, together with an analy-
sis of symptoms that discriminate signifi-
cantly among patients with pheochromo-
cytoma and patients with either panic or
generalized anxiety disorder, is reported
elsewhere (29).)
One pheochromocytoma-positive pa-
tient was diagnosed as possible panic dis-
order. Two patients met criteria for gen-
eralized anxiety disorder, and two others
were diagnosed as "possible generalized
anxiety disorder." Of the four patients
with definite or possible generalized anx-
iety disorder, three were also diagnosed
as having a major depressive episode; two
of these three patients were quite ill with
malignant pheochromocytoma and multi-
organ involvement.
The five patients who received a diag-
nosis, definite or possible, of generalized
anxiety (four patients) or panic disorder
(one patient) had mean plasma E levels
significantly higher than those of the
other 12 patients (Kruskal Wallis ANOVA
for nonparametric data: 2983 ± 4493 pg/
ml versus 102 ± 90 pg/ml, p < 0.02). There
was a trend toward higher mean NE levels
in this group as well. Individual values
are given elsewhere (29).
Pheochromocytoma-negative patients.
In the pheochromocytoma-negative sam-
ple of 25 patients, 2 had panic disorder, 2
had generalized anxiety disorder, and 3
received diagnoses of both panic disorder
and generalized anxiety (at least one def-
inite). In the pheochromocytoma-negative
group, there were no significant differ-
ences in mean levels of plasma or urine E
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or NE between patients with and without
a DSM-III anxiety disorder diagnosis.
Correlations of Anxiety Scores and
Catecholamine Levels
Norepinephrine. In the pheochromocy-
toma-positive group, NE was not signifi-
cantly correlated with scores on any of
the four anxiety scales studied (SCL-90R
Anxiety; SCL-90R Phobic Anxiety; Spiel-
berger State; Spielberger Trait).
In contrast, in the pheochromocytoma-
negative group, plasma NE was signifi-
cantly correlated with scores on all four
anxiety scales. These results are shown in
Table 2, upper half. When the 7 pheo-
chromocytoma-negative patients with a
DSM-III diagnosis were excluded from the
analysis, the correlations between plasma
NE and the anxiety scales for the remain-
ing 18 pheochromocytoma-negative pa-
tients remained significant, and became
even stronger.
In the panic disorder patients, too,
plasma NE showed a significant correla-
tion with scores on the SCL-90R Anxiety
scale. As noted previously, the Spielber-
ger Anxiety Scales were not administered
to this group. These results are also shown
in Table 2.
In order to specify more precisely the
nature of the relationship, we further sub-
divided the 10 items comprising the SCL-
90R Anxiety scale into three groups: five
items that describe cognitive aspects of
anxiety, two that are mixed cognitive and
somatic, and three that are primarily so-
matic. These subgroups and the following
results are shown in Table 3. In the phe-
ochromocytoma-positive patients, NE was
not significantly correlated with any of
the 10 individual items comprising the
SCL-90R Anxiety scale. In the pheochro-
mocytoma-negative patients, plasma NE
was significantly correlated with four of
the five items that are related to the cog-
nitive experience of anxiety. In contrast,
plasma NE was significantly correlated
with only one of the five noncognitive or
mixed items: heart racing or pounding,
TABLE 2. Correlations of SCL-90R and Spielberger Scales with Catecholamines (Pearson's Product-
Moment Correlation Coefficients)
SCL-90R Anxiety Scale
SCL-90R Phobic Anxiety
Spielberger State Anxiety
Spielberger Trait Anxiety
SCL-90R Anxiety Scale
SCL-90R Phobic Anxiety
Spielberger State Anxiety
Spielberger Trait Anxiety
Pheochromocytomc
positive
Plasma
NS
NS
NS
NS
NS
NS
NS
NS
Urine
NS
NS
NS
NS
NS
NS
NS
NS
i Pheochromocytoma
negative
Plasma Urine
Correlation coefficients for NE
+0.40* NS
+0.55* NS
+0.44* NS
+0.49* NS
Correlation coefficients for E
NS NS
NS -0.57**
NS NS
NS NS
Panic
Plasma
+0.67*
NS
NA*
NA
NS
NS
NA
NA
Urine
NS
NS
NA
NA
NS
NS
NA
NA
'p<0.05.
l*p<0.01.
' NA = not available.
Psychosomatic Medicine 52:129-142 (1990) 135M. N. STARKMAN et al.
TABLE 3. Correlations of SCL-90R Anxiety Scale Individual Items with Norepinephrine (Pearson's
Product-Moment Correlation Coefficients)
Cognitive
Fearful
Suddenly scared for no rea-
son
Sudden spells terror
Something bad will happen
Frightening thoughts
Mixed Cognitive/Somatic
Nervous, shaky
Tense, keyed up
Somatic
Trembling
Restlessness
Heart racing, pounding
Pheochromocytoma
positive
Plasma
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
Urine
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
Pheochromocytoma
negative
Plasma
+0.55**
+0.68**
+0.46*
NS
+0.55**
NS
NS
NS
NS
+0.43*
Urine
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
Panic dis<
Plasma
NS
NS
t
NS
+0.63*
NS
NS
+0.56*
NS
+0.68*
Drder
Urine
NS
NS
NS
NS
NS
NS
NS
NS
NS
*p<0.05.
**p<0.01.
t Unable to calculate: all rated maximum.
which is consistent with its inotropic and
chronotropic effects on the heart. Urinary
NE showed nonsignificant trends in the
same direction for the SCL-90R Anxiety
scale and its individual items. For the
panic disorder patients there were a few
scattered positive correlations of individ-
ual items with NE.
Epinephrine. In contrast to NE, E levels
were not positively correlated with scores
on any of the four Anxiety scales in any
of the three groups studied. In fact, urine
E was inversely correlated with the SCL-
90R Phobic Anxiety scale in the pheo-
chromocytoma-negative group. These re-
sults are shown in Table 2, lower half.
When the 10 items of the SCL-90R Anx-
iety scale were analyzed separately,
plasma E levels in the pheochromocy-
toma-positive group were significantly
correlated with three of the five somatic
or mixed cognitive/somatic items (nerv-
ous, shaky r = +0.48, p < 0.05; tense,
keyed up r = +0.57, p < 0.05; trembling r
= +0.56, p < 0.05). In the pheochromo-
cytoma-negative group, urinary E showed
an inverse correlation with three of the
five items related to the cognitive expe-
rience of anxiety (fearful r = -0.40, p <
0.05; suddenly scared for no reason r =
—0.40, p < 0.05; frightening thoughts r =
-0.51, p < 0.05). When the seven pheo-
chromocytoma-negative patients with a
DSM-III Anxiety diagnosis were excluded,
these inverse correlations between uri-
nary E, the SCL-90R Phobic Anxiety scale
and cognitively experienced individual
items of the SCL-90R Anxiety scale for
the remaining 18 pheochromocytoma-
negative patients remained significant.
In the panic disorder patients, no sig-
nificant correlations were found for E lev-
els and any of the individual items of the
SCL-90R Anxiety scale.
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Correlation of Somatic Symptoms and
Catecholamine Levels
The SCL-90R Somatization scale in-
cludes 12 items related to physical symp-
toms such as faintness, weakness, nausea,
tingling, dyspnea, and hot or cold spells.
Plasma E in the pheochromocytoma-
positive group was positively correlated
with scores on the somatization scale: r =
+0.51, p < 0.05. Plasma E in the pheo-
chromocytoma-negative group was also
positively correlated with scores on the
somatization scale: r = +0.41, p < 0.05.
When the 18 pheochromocytoma-nega-
tive patients without a DSM-III anxiety
diagnosis were analyzed separately, this
correlation remained and increased to r =
+0.55. p< 0.05.
In contrast, NE in plasma or urine was
not significantly correlated with scores on
the somatization scale in either the phe-
ochromocytoma-positive or pheochromo-
cytoma-negative patient group.
In the panic disorder patients, neither
E nor NE was significantly correlated with
scores on the SCL-90R Somatization scale.
DISCUSSION
Despite major elevations in peripheral
catecholamine levels and considerable
physical symptoms, the great majority of
the pheochromocytoma-positive patients
we studied did not meet DSM-III criteria
for panic or generalized anxiety disorder.
None of 17 such patients we studied de-
scribed the severe apprehension or fear
characteristic of panic attacks. In fact,
over 50% of our sample denied having
significant psychologic symptoms of any
sort (29). In the pheochromocytoma-posi-
tive patient group, there was no signifi-
cant correlation between anxiety, as
measured by four standard scales, and
plasma NE or E levels. Somatic symptoms,
however, were correlated with plasma E
levels, which is consonant with our
knowledge of the peripheral effects of E.
Since systemic catecholamines do not
cross the blood-brain barrier in physiolog-
ically significant amounts (23-25), these
results suggest that increased peripheral
catecholamines secreted by a source au-
tonomous of nervous system control and
stimulation are not sufficient to elicit se-
vere anxiety as defined by DSM-III crite-
ria in the majority of patients, even
though considerable physical symptoms
are experienced.
There are several possible caveats to
this conclusion. First, the five pheochro-
mocytoma-positive patients with definite
or possible diagnosis of anxiety disorder
had plasma E levels significantly higher
than those of the other patients. Three of
these five patients had malignant pheo-
chromocytoma with metastatic disease,
which might account for their anxiety
symptoms as well as the additional major
depressive disorder diagnosis found in
two of the three. Nevertheless, the possi-
bility exists that extremely elevated cate-
cholamine values may play some etiologic
role in the production of anxiety. Second,
down-regulation of peripheral catechol-
amine receptors may have occurred over
time in patients with pheochromocyto-
mas, perhaps leading to decreased respon-
siveness to the elevated catecholamine
levels. Against this possibility is the fact
that the pheochromocytoma-positive pa-
tients reported no differences in their cur-
rent symptoms versus their initial ones.
Despite chronic exposure to elevated cat-
echolamines, they reported continuing
major episodes of tachycardia, restless-
ness, shortness of breath, and gastrointes-
tinal symptoms. Third, adrenoreceptor
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blocking agents may have affected the
patients' experience of anxiety, even
though elevation of blood pressure and
heart rate continued despite such medi-
cations. Against this possibility is the fact
that treating psychiatric patients with
generalized anxiety disorder and panic
disorder with propranolol, a /?-adrenergic
blocking medication which readily enters
the brain, has been largely unsuccessful
except for decreasing some of the somatic
symptoms of anxiety. In our study, pheo-
chromocytoma-positive patients receiv-
ing /3-adrenergic blocking medications
had no less psychological or somatic
symptomatology than the other patients
with pheochromocytoma, as shown by
Student's t test. The pheochromocytoma-
negative group provided the opportunity
to examine further the possible role of
these antihypertensive medications. In
this group, Student's t tests revealed no
significant differences in plasma and uri-
nary E and NE levels between subgroups
of patients receiving and not receiving
such medications. Similarly, there were
no significant differences in the anxiety
scales for patients on, or not on, medica-
tion. Medication did not reduce the so-
matic symptoms experienced by patients;
rather, the SCL-90R Somatization scale,
which includes headaches, chest pain,
and nausea, was higher in patients who
were taking medication (p < 0.03). Lastly,
opioid peptides known to be secreted by
pheochromocytomas might possibly mod-
ulate and have reduced the degree of
stimulation of peripheral receptors by cat-
echolamines.
In contrast to the patients with pheo-
chromocytomas, in the pheochromocy-
toma-negative patients, anxiety ratings
were significantly correlated with plasma
NE levels. Again, plasma E showed no
significant correlations with any of the
four anxiety scores. Moreover, plasma NE
was significantly correlated with individ-
ual items of the SCL-90R Anxiety scale
related to the cognitive experience of anx-
iety, but not with items related to the
somatic symptoms of anxiety. In indi-
viduals without a pheochromocytoma,
plasma NE reflects sympathetic nervous
system activity; the most direct evidence
for this observation is provided by the
correlation of plasma NE with levels of
sympathetic activity measured electro-
physiologically in muscle (34). The pat-
terns of correlations we observed in
the pheochromocytoma-negative patients
suggests the hypothesis that anxiety orig-
inating and experienced cognitively may
activate and be linked to the degree of
stimulation of the sympathetic nervous
system. Thus, NE in the periphery is, at
least in part, a marker of this central stim-
ulation. There is some evidence that sup-
ports the hypothesis that peripheral NE
reflects increased activity of central nor-
adrenergic neurons. In 159 subjects (most
of whom had neurologic disease), there
was a strong relationship between NE lev-
els in blood and CSF (r = +0.78, p < 0.001),
despite the effective blood-CSF barrier for
NE (35). Maas et al. (36) suggest that
neuro-anatomic, physiologic, pharmaco-
logic, and biochemical evidence indicate
a close coupling of functional activity of
the sympathetic nervous system and the
catecholamine systems in the central
nervous system, so that increased impulse
flow in central nervous system catechol-
amine systems is linked to increased im-
pulse flow in the sympathetic nervous
system.
In the pheochromocytoma-negative pa-
tients, urinary E was inversely correlated
with the cognitive manifestations of anx-
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iety. The fact that the urinary ratio of NE
to E also showed significant correlations
with the SCL-90R Anxiety (r = +0.50, p
< 0.05) and Phobic Anxiety (r = +0.70, p
< 0.01) scales further supports the finding.
One speculation regarding these results is
that psychic anxiety preferentially acti-
vates the noradrenergic limb of the sym-
pathetic system, possibly at the "expense"
of the epinephrine-secreting adrenal
medulla-activatinglimb. In humans, disso-
ciated responses by the sympathetic nerv-
ous system and adrenal medullary cate-
cholamine release do occur in response to
various stimuli (37). However, further
speculation should probably await confir-
mation of our finding.
Excluding the seven patients with a
DSM-III diagnosis from the analysis of
the pheochromocytoma-negative group
strengthened the correlations between
plasma NE, the anxiety scales, and the
individual items of the SCL-90R Anxiety
scale. This indicates that the correlations
for the group as a whole do not result only
from the contribution of patients with a
clinically diagnosable anxiety disorder. In
fact, the opposite was seen: there were no
correlations between plasma NE and the
anxiety scales in the subgroup with a di-
agnosable anxiety disorder. On the one
hand, this lack of correlation in the anxi-
ety disorder patients may be artifactual.
The number of subjects was small, mak-
ing it difficult to achieve significance.
Furthermore, one individual item of the
SCL-90R Anxiety subscale: fearfulness,
did show a significant correlation with
plasma NE (r = +0.82, p < 0.05), and two
other cognitive items showed substantial
although statistically nonsignificant cor-
relations: suddenly scared (r = +0.65, p <
0.11) and sudden spells of terror (r =
+0.58, p < 0.17). On the other hand, if the
finding is not artifactual, one could spec-
ulate that the patients with anxiety dis-
orders differ from the remainder of the
pheochromocytoma-negative group in
that they manifest a dissociation of the
degree of cognitively experienced anxiety
and the magnitude of peripheral elevation
of NE levels. (For example, these patients
might hypersecrete NE so that even low
levels of anxiety produce large NE re-
sponses. Or, they might have a depleted
store of NE due to chronic release, and
therefore no ability to respond with
greater catecholamine release in the face
of greater anxiety.)
The pheochromocytoma-negative pa-
tients we studied may represent a popu-
lation with a specific pattern of catechol-
amine response to anxiety-provoking
stimuli. They were initially sent for eval-
uation precisely because their paroxys-
mal or sustained hypertension was asso-
ciated with elevated catecholamine
levels. During our study, plasma cate-
cholamines were obtained preceding an
anxiety-provoking situation: a medical in-
vestigation. These patients may represent
that proportion of the population that re-
sponds to certain conditions of stress and
anxiety by elevation of NE and responsiv-
ity of the vascular system. There is still
controversy over whether or not there
exists a subgroup of hypertensive patients
with elevated basal levels of catechol-
amines and excessive sympathetic nerv-
ous system responsiveness to stress (38,
39). This study would tend to support
such a hypothesis.
In summary: 1) None of the patients
with pheochromocytoma met DSM-III cri-
teria for panic disorder, while two met
criteria for generalized anxiety disorder.
Since peripheral catecholamines do not
cross the blood-brain barrier, the periph-
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eral effects of E and NE secreted by a
source autonomous of central nervous
system control were not sufficient to elicit
anxiety disorders meeting DSM-III criteria
in the majority of such patients.
2) E levels were not significantly cor-
related with any of the four anxiety scales
in any of the three patient groups studied.
In both the pheochromocytoma-positive
and pheochromocytoma-negative pa-
tients, E was significantly correlated with
the SCL-90R Somatization Scale, which
measures 12 physical symptoms.
3) NE levels were not significantly cor-
related with any of the four anxiety scales
in patients with pheochromocytoma. In
contrast, in patients without pheochro-
mocytoma and in patients with panic dis-
order, plasma NE was significantly corre-
lated with the anxiety scales.
4) When the 10 items of the SCL-90R
Anxiety scale were categorized according
to whether they measured a cognitive or
somatic aspect of anxiety, plasma E levels
in the pheochromocytoma-positive pa-
tients were significantly correlated with
three of five somatic or mixed cognitive/
somatic items, but not with any of the five
cognitive items. In the pheochromocy-
toma-positive patients, plasma NE levels
were not significantly associated with any
individual items. In contrast, plasma NE
in pheochromocytoma-negative patients
was significantly correlated with four of
five items related to the cognitive expe-
rience of anxiety, but only one of five
noncognitive items.
Taken together, these observations and
patterns of correlations support the hy-
pothesis that in individuals without an
autonomous source of peripheral cate-
cholamines, NE in the periphery (which
is primarily the result of spillover from
vascular beds in muscle) results from
sympathetic nervous system activity and
probably reflects, rather than causes, anx-
iety.
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